Form 8-K - Current report:
SEC Accession No. 0001104659-26-077339
Filing Date
2026-06-24
Accepted
2026-06-24 16:54:19
Documents
16
Period of Report
2026-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2618105d1_8k.htm   iXBRL 8-K 31051
2 EXHIBIT 1.1 tm2618762d1_ex1-1.htm EX-1.1 247435
3 EXHIBIT 5.1 tm2618762d1_ex5-1.htm EX-5.1 55327
4 EXHIBIT 99.1 tm2618762d1_ex99-1.htm EX-99.1 13060
8 GRAPHIC tm2618762d1_ex5-1img001.jpg GRAPHIC 1956
9 GRAPHIC tm2618762d1_ex99-1img001.jpg GRAPHIC 3626
  Complete submission text file 0001104659-26-077339.txt   593837

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA qure-20260623.xsd EX-101.SCH 3011
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE qure-20260623_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qure-20260623_pre.xml EX-101.PRE 22356
19 EXTRACTED XBRL INSTANCE DOCUMENT tm2618105d1_8k_htm.xml XML 3128
Mailing Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM Netherlands 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 261116619
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)